101 Orchard Ridge Drive, Suite 1E
Gaithersburg, MD 20878
Phone: 240-683-4500

Kevin P. Chance, founder, director and CEO
Privately Held


Aptus Genomics Inc. is a biotechnology company focused on elucidating the biological functions and disease associations of G protein-coupled receptor (GPCR) genes and developing drugs that target the receptors encoded by these genes for use as therapeutics to treat human diseases. G protein-coupled receptors are known to play a key role in disease symptoms and disease progression for many indications. The company uses molecular biology and information technology to develop a technology platform to discover, qualify and use families of human genes for pharmaceutical research.

AptuScreen is a proprietary, high-throughput assay that measures the kinetics of both secondary messengers of GPCR activation, calcium and cyclic AMP. The company says this is the first, and only, rapid, low-cost technology that provides an accurate, physiologically relevant, kinetic evaluation of GPCR/ligand binding in living cells, using industry-standard instrumentation.

Aptus has a collection of approximately 310 full-length, sequence-verified, expression-ready human GPCR genes. Approximately 25 of these genes are proprietary to Aptus. It also has a full set of GPCR discovery biology assets (e.g., expression profiling, membrane binding assays, transcription reporter assays, promiscuous and chimeric G proteins, etc.), complemented by its bioinformatics platform.


Aptus is in discussions with potential collaborators.